Oncolitics biotch is a junior research biotech company with one " drug" called Pelareorep.
aka Pela.
Onc has been in trials for over 20 years. As such & within , have proven. With 1000s of patients.
Pela only multiples in cancer cells. Making its delivery very safe.
one of very few cancer treatments that can be delivered through I.V.
giving Pela a very competitive advantage.
Does not need to be inter- Tumor delivery...it finds the cancer.
Eraly trial lead to the discovery of " turning cold tumours hot"..meaning your immune system can see the tumour, which previously was hidden.
Recent trials ( all co- therapy), with Roche, Pfizer, Incyte, B.m.s. & Merck; All are looking to identify efficacy & improments or expansion of their existing markets.
Pela for example, Can exapand an existing patient base of response by multiples....by lighting up the tumour.
In 2017, a mbreast cancer trail showed results leading to a partnership with A.N.
Most recently a co- therapy trial with Roche, demonstrated amazing results. With a very hard to treat pancreatic cancer.
That was significant enough to bring about FDA fast track designation, in a matter of a few months.
A few take to heart to attack me. Yet, I am meaningless.
What is important are the development facts TODAY,
Roche, Pfizer, Incyte, Merck ...would never put there good names or drugs on the line without Wide & deep resurch.
The panc results for example with Tecentriq, a lead cancer & standard of care.
Roche would never risk the good name of the drug or their company without muktiple due diligence.
Both for Pela & ONC as a company.
so throwing random statements out based on share price activity, is very miss information.
so again a challenge to anyone who is so well informed. Please let the executives of the above mentioned worlD leader pharma companies.your astute information that they are all wasting their time.
bottom line
onc has had a long journey.
now they have great collaborations to assist in the journey.
should they sucseed . Oncolitics biotech will be worth billions.
should they fail, not much less then now.